What Is the Best Way to Stop Drinking Alcohol?

Quitting alcohol safely involves more than willpower. Learn about medications, therapy, and support options that make lasting recovery more achievable.

There is no single best way to stop drinking alcohol, because the approach that works depends on how much you drink, how long you have been drinking, whether you have other health conditions, and what your personal goals are. What the research does show is that combining strategies tends to outperform any single method on its own, and that both medications and behavioral therapies have strong evidence behind them. The more interesting finding, though, is how many effective options exist and how poorly matched most people are to the ones that would help them most.

Why You Should Not Just Stop Cold Turkey

If you have been drinking heavily for a long time, abruptly quitting without medical guidance can be genuinely dangerous. Alcohol withdrawal ranges from mild tremors and anxiety to a severe, life-threatening condition called delirium tremens, which can involve hallucinations, seizures, and agitation severe enough to be fatal if left untreated. The underlying biology is straightforward: chronic heavy drinking suppresses the brain’s excitatory signaling. When alcohol is suddenly removed, that signaling rebounds far past normal levels, producing a dangerous state of neural overexcitement. Patients may present with anything from mild shakiness to full-blown seizures.

Not everyone needs an inpatient stay. Research comparing home-based detox with hospital detox has found that completion rates and complication rates are similar for people whose withdrawal risk is assessed as moderate. A systematic review of community detoxification programs found high completion rates, good safety profiles, and often better drinking outcomes afterward compared with facility-based detox, at lower cost. The key is getting a proper assessment first. A doctor can score your withdrawal risk and decide whether you can safely taper at home with medication support or whether you need closer monitoring.

Medications That Help

Three medications are approved in the United States specifically for alcohol use disorder, and each works differently. Understanding those differences matters because the right choice depends on your goal and your biology.

Naltrexone blocks opioid receptors in the brain, dampening the pleasurable buzz you get from drinking. It is particularly useful if your goal is to cut back rather than quit entirely, because it reduces craving and heavy drinking. A meta-analysis found that naltrexone had a larger effect than acamprosate on reducing heavy drinking days and cravings. Imaging research has shown that the degree to which naltrexone reduces drinking is tied to individual differences in opioid receptor availability in certain brain regions. In other words, it works better for some people than others based on brain chemistry, which we will come back to later.

Acamprosate works on a different system. It helps restore the balance between excitatory and inhibitory brain signaling that gets disrupted by chronic alcohol use. Where naltrexone excels at cutting heavy drinking, acamprosate has a larger effect on maintaining total abstinence, as the same meta-analysis noted. It appears to calm the post-withdrawal surge in excitatory brain chemicals that drives anxiety and restlessness in early sobriety. Its track record across more than 25 placebo-controlled trials is solid for keeping people from returning to any drinking.

Disulfiram (Antabuse) takes a fundamentally different approach: it makes you sick if you drink. It blocks an enzyme involved in alcohol metabolism, so consuming even a small amount of alcohol leads to nausea, flushing, and headaches. The evidence for disulfiram is a bit awkward. A meta-analysis found that it worked in open-label trials, where patients knew they were taking the real drug, but showed no advantage over placebo in blinded trials, where patients did not know. That suggests its main power is psychological: knowing you will feel terrible if you drink acts as a deterrent. A recent study in patients with severe alcohol use disorder found that disulfiram as part of addiction-focused treatment helped patients resist craving episodes and avoid impulsive drinking. So it works, but primarily through the fear of consequences rather than a direct pharmacological effect on craving.

Beyond these three, gabapentin has emerged as a promising off-label option. Originally developed for seizures, gabapentin reduces drinking, craving, and alcohol-related sleep problems and mood disturbances in the months after quitting. Its appeal is practical: it is easy to dose, can be increased quickly, and addresses both the withdrawal phase and the longer-term maintenance phase. Topiramate, another anticonvulsant, also has good evidence for reducing heavy drinking in outpatient settings.

Therapy and Behavioral Approaches

Medication alone is rarely the whole answer. Combining medication with behavioral therapy consistently leads to higher abstinence rates, less heavy drinking, and better mental health and quality of life than either strategy alone. That said, the relationship between medication and therapy is not always simply additive. The large COMBINE study, one of the most rigorous trials in this field, found that adding a combined behavioral intervention on top of naltrexone did not produce better outcomes than naltrexone or the behavioral intervention alone. The takeaway is not that combining approaches is pointless, but that more is not always more. Having good medication or good therapy gets you most of the benefit; layering both at maximum intensity does not necessarily double it.

Cognitive behavioral therapy and motivational interviewing are the best-studied psychological approaches. A meta-analysis found them effective for reducing both alcohol consumption and depression, which frequently co-occur. CBT teaches you to recognize the situations, emotions, and thought patterns that trigger drinking, then practice alternative responses. Motivational interviewing is less about teaching skills and more about helping you clarify why you want to change and building internal motivation. Both are typically delivered in about a dozen sessions.

Contingency management is a less well-known approach that deserves attention. It provides tangible rewards, often small cash payments or vouchers, for meeting drinking targets verified by biological testing. A meta-analysis found that people receiving contingency management were roughly three times more likely to provide alcohol-negative samples compared with controls. In one trial of people with both alcohol problems and serious mental illness, contingency management participants achieved about an extra week and a half of abstinence during a 12-week intervention. The idea feels transactional, but the evidence is hard to argue with.

Peer Support Groups

Alcoholics Anonymous remains the most widely recognized peer support option, and large observational studies suggest that regular AA attendance is associated with improved outcomes. Its 12-step framework appeals to people who benefit from spiritual or community grounding. But it is not the only option, and it is a poor fit for some people.

SMART Recovery, which uses a cognitive-behavioral self-management framework instead of the 12-step model, attracts a somewhat different population. Research comparing the two found that people choosing SMART-only tended to have lower clinical severity, higher incomes, and more education, while those choosing AA-only or both typically had more intensive treatment histories and higher alcohol use severity. Neither program is objectively “better.” The right fit depends on your personal preferences and how severe the problem is.

Does It Have to Be Total Abstinence?

One of the most loaded questions in alcohol treatment is whether cutting back to moderate, controlled drinking is a realistic alternative to quitting entirely. The traditional clinical answer has been that true alcohol dependence requires total abstinence. The evidence is more nuanced than that.

A long-term study tracking people for ten years after treatment found that the highest-functioning groups at three years, regardless of whether they were abstinent or drinking at low levels, maintained the best psychological health at the ten-year mark. Being abstinent at three years did not predict better psychological functioning at ten years compared with people who were drinking moderately. A systematic review and meta-analysis comparing controlled-drinking goals with abstinence goals found that the effectiveness of the two approaches did not clearly depend on how severe the person’s alcohol problem was.

This does not mean that everyone can safely moderate. For many people with severe dependence, controlled drinking is a gateway back to heavy use. But for others, especially those with milder problems, a harm-reduction goal of drinking less can be a valid path. The practical implication: if the demand for total abstinence is keeping you from seeking help at all, know that evidence-supported reduced-drinking programs exist and can improve your health even if you are not ready to quit completely.

What Happens to Your Body and Brain When You Stop

The brain begins recovering surprisingly quickly after you stop drinking. Brain imaging studies have shown measurable increases in brain volume within just weeks of abstinence, averaging close to two percent globally, with the greatest gains around areas involved in attention and coordination. Attention performance improved in step with these structural changes. Some of this recovery continues over months and years, though imaging research also indicates that some alcohol-related brain changes appear to be permanent.

Sleep is one of the most frustrating early challenges. Insomnia during and after withdrawal is common, and poor sleep during this window is itself a risk factor for relapse. Sleep disturbances can persist for months into recovery. Addressing sleep problems early, whether through behavioral sleep hygiene techniques, gabapentin (which has the advantage of helping both cravings and insomnia), or other means, is an underappreciated part of a recovery plan.

Nutritional recovery matters too. Heavy drinkers are often deficient in thiamine (vitamin B1), and restoring thiamine levels has been linked to improvements in memory function, even in people who have not yet developed the severe neurological damage associated with Wernicke’s encephalopathy. Supplementation is cheap, safe, and routinely recommended in the early weeks of sobriety.

Post-Acute Withdrawal and the Relapse Window

Getting through the first week or two of detox is only part of the battle. Many people experience a prolonged set of symptoms, sometimes lasting weeks to months, that include anxiety, irritability, sleep problems, and difficulty concentrating. These post-acute withdrawal symptoms are tied to lasting changes in stress hormones, brain reward circuits, and other neurobiological systems, and they are a recognized risk factor for returning to drinking. Withdrawal-related anxiety in particular reflects adaptations in the body’s stress response system that do not snap back to normal the moment you stop drinking.

This is one reason why continuing care after the initial treatment phase matters so much. Smartphone-based recovery support tools have shown genuine promise here. A randomized trial found that patients using a recovery support app called A-CHESS reported significantly fewer risky drinking days (about 1.4 days versus 2.8 days per month) and higher odds of abstinence at the 8- and 12-month marks. A later trial comparing telephone-based and smartphone-based continuing care found that both reduced risky drinking days compared with treatment as usual, cutting them roughly in half. A systematic review of smartphone interventions for substance use confirmed that app-based programs can be an effective alternative to traditional forms of continuing care. These tools are not a replacement for therapy or medication, but they fill a gap: they are available at 2 a.m. when a craving hits and your therapist is not.

People Who Quit Without Formal Help

A surprising chunk of people with alcohol problems resolve them without any formal treatment. A quantitative review of the literature found that roughly one in five people with substance abuse problems (including alcohol) achieved remission on their own, using a narrow definition of remission, and about one in four using a broader definition. A long-term study following drug users over 25 years found that most who had started using by their early twenties gradually achieved remission, and the majority did not use traditional treatment in their final quit attempts.

The factors that self-remitters cite as important tend to fall into two groups: triggers that started the change (health scares, pressure from family and friends, major life events) and factors that sustained it (social support, building friendships with people who do not drink heavily, a shift in identity). That said, estimates of untreated remission vary widely depending on how researchers define it and who they study. This is not an argument against seeking treatment. It is a reminder that problem drinking exists on a spectrum, and for those on the milder end, environmental and social changes alone can sometimes be enough.

Exercise as a Recovery Tool

Physical activity is easy to overlook as a treatment component, but research supports its role. Animal studies have found that regular exercise significantly reduces withdrawal symptoms and lowers stress hormone levels to a degree comparable to benzodiazepine treatment, and that the combination of exercise and medication outperforms either alone. The practical translation for humans: regular physical activity during recovery helps with mood, sleep, stress management, and the general restlessness that makes early sobriety so uncomfortable. It is free, it has no side effects worth worrying about, and it directly addresses several of the post-acute withdrawal symptoms that put people at risk for relapse.

Genetic Factors in Medication Choice

One of the more promising frontiers in alcohol treatment is figuring out which medication will work best for a given person before they start taking it. Naltrexone is the furthest along in this area. A meta-analysis found that people who carry a particular variant of the mu-opioid receptor gene (the G allele of the A118G polymorphism) had about twice the odds of benefiting from naltrexone compared with those who did not carry it. More recent work has refined this picture further, showing that the interaction between opioid receptor genes and dopamine-related genes may predict response even more precisely.

The picture is not perfectly clear yet. At least one large Veterans Affairs cooperative study found no significant interaction between this same opioid receptor gene variant and naltrexone response. Similarly, acamprosate may work best in people with elevated baseline levels of glutamate, one of the brain chemicals it targets. In clinical studies, people who started with high glutamate levels responded well to acamprosate, while those who started with low levels showed no benefit. Routine genetic or biomarker testing before prescribing is not yet standard practice, but it is where the field is heading.

Psilocybin-Assisted Therapy

Among newer experimental approaches, psilocybin-assisted psychotherapy has generated notable results. A randomized clinical trial found that participants who received two psilocybin sessions alongside therapy reported heavy drinking on about 10 percent of days over a 32-week follow-up period, compared with about 24 percent of days in the control group. Average daily alcohol intake was also lower in the psilocybin group, with no serious adverse events. Brain imaging work offers a possible explanation for why: psilocybin appears to increase activity in prefrontal brain regions involved in decision-making and emotional regulation, while dampening activity in areas linked to craving and habitual responses. This is still early-stage research from single-site trials, and psilocybin is not yet an approved treatment. But the effect sizes are large enough that larger trials are underway, and it represents a genuinely different mechanism than anything currently available.